Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure
A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure
Sponsor: Can-Fite BioPharma
This PHASE2 trial investigates Glaucoma and Ocular Hypertension and is currently completed. Can-Fite BioPharma leads this study, which shows 11 recorded versions since 2010 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jun 2022 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Jun 2022 [monthly]
Completed PHASE2
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jun 2018 — Jun 2019 [monthly]
Unknown Status PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Feb 2017 — Feb 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Oct 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Can-Fite BioPharma
For direct contact, visit the study record on ClinicalTrials.gov .